3rd Quarter - Report

ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$408,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 20, 2011 $408,000 Replaced
3rd Quarter - Amendment Jan 20, 2012 $410,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MARY LACEY REUTHER —
MICHAEL RUGGIERO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1249 (112th), S. 23 (112th)

Taxation/Internal Revenue Code TAX

Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MARY LACEY REUTHER —
MICHAEL RUGGIERO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MARY LACEY REUTHER —
MICHAEL RUGGIERO —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2182 (112th)

Medicare/Medicaid MMM

Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
BRIAN CORRIGAN —
MARY LACEY REUTHER —
MICHAEL RUGGIERO —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.